Abstract:Background: Heavy menstrual bleeding (HMB) negatively impacts quality of life directly and indirectly due to symptoms associated with resultant iron deficiency (ID) and iron deficiency anemia (IDA). Antifibrinolytics, to decrease blood loss, and iron supplementation, to replace deficits, should be cornerstones of HMB management. Despite an abundance of evidence supporting their effectiveness and safety, clear, consistent guidance on treating HMB and secondary ID/IDA is lacking which renders access to care suboptimal and inequitable. Objective: To identify barriers and facilitators to health care provider (HCP) access of oral antifibrinolytic agents and iron supplementation for patients with HMB globally. Methods: We conducted a global survey on HCPs' experience in accessing antifibrinolytics, oral and intravenous (IV) iron. Participants were identified via snowball sampling using professional connections and/or social media. Descriptive analysis was used. Given the voluntary nature of our survey, the total number of responses varied with each question. This study was approved by the institutional research ethics board. Results: A total of 113 HCPs responded, and practiced in North America (74%), Europe (17%), Central and South America (2%), Middle East (2%), Africa (1%), and Australia (1%). Specialties included obstetrics and gynecology (41%), hematology (21%), family medicine (16%), internal medicine (11%), pediatrics (9%), and maternal fetal medicine (1%). See Figures 1 and 2 for antifibrinolytic and iron barriers by region, respectively. Antifibrinolytic Top Global Barriers: survey respondents reported product monograph contraindications (50/103, 49%), prescription requirement (46/103, 45%), lack of insurance coverage (34/103, 33%), patient safety concerns and drug cost (both 33/103, 32%). Antifibrinolytic Top Global Facilitators: HCPs reported access to websites for knowledge translation (35/85, 41%), readily available education materials (27/85, 32%), and drug access navigators (16/85, 19%). Oral Iron Top Barriers: HCPs reported patient concern regarding adverse effects of oral iron (64/101, 63%), inappropriately low ferritin reference ranges (38/101, 38%), drug cost (36/101, 36%), lack of private insurance coverage (27/101, 27%), and lack of public insurance coverage (26/101, 26%). Oral Iron Top Facilitators: HCPs reported readily available education materials (43/82, 52%), websites for knowledge translation (33/82, 40%), and drug access navigators (19/82, 23%). IV Iron Top Barriers: HCPs reported lack of infusion center capacity (58/101, 57%), drug cost (51/101, 51%), administrative burden (50/101, 50%), lack of public insurance coverage (40/101, 40%), and lack of private insurance coverage (37/101, 37%). IV Iron Top Facilitators: HCPs reported publicly funded infusion clinics (55/99, 56%), private infusion clinics (29/99, 29%), readily available education materials (25/99, 25%), websites for knowledge translation (23/99, 23%), and drug access navigators (21/99, 21%). Conclusions: Despite geographical variability in funding of health services and medications, there was a surprising consistency in the top reported barriers and facilitators to antifibrinolytic and iron access among international survey respondents. A key limitation is the predominant representation from North American and European countries. Further research in other regions is needed to allow us to gauge and address global barriers and facilitators more comprehensively.

A Review of Clinical Guidelines on the Management of Iron Deficiency and Iron-Deficiency Anemia in Women with Heavy Menstrual Bleeding

Heavy menstrual bleeding, iron deficiency, and iron deficiency anemia: Framing the issue

Effects of anemia and iron deficiency on quality of life in women with heavy menstrual bleeding

Standardizing the evaluation and management of iron deficiency anemia secondary to heavy menstrual bleeding in the emergency department

Assessment of Iron Status in Adolescents Presenting to the Emergency Department With Heavy Menstrual Bleeding

The relationship between menorrhagia, iron deficiency, and anaemia in recreationally active females: an exploratory population based screening study

Efficiency of intravenous iron carboxymaltose in patients with iron-deficiency anemia due to heavy menstrual bleeding: a single-center experience

The relationship between heavy menstrual bleeding, iron deficiency, and iron deficiency anemia

Recommendations for diagnosis, treatment, and prevention of iron deficiency and iron deficiency anemia

Iron deficiency anemia: Impact on women's reproductive health

Identification of women and girls with iron deficiency in the reproductive years

Treatment Modalities in Adolescents Who Present with Heavy Menstrual Bleeding

Overview of iron deficiency and iron deficiency anemia in women and girls of reproductive age

Treatment of anemia using parenteral iron supplements

Iron Deficiency in Women's Health: New Insights into Diagnosis and Treatment

Practical guidance for the management of iron deficiency in patients with inflammatory bowel disease

Clinical practice guidelines on menorrhagia: management of abnormal uterine bleeding before menopause

Iron deficiency anaemia: pathophysiology, assessment, practical management

Facilitators and Barriers to Accessing Antifibrinolytic and Iron Therapies for Patients Who Menstruate - a Global Healthcare Provider Survey

How we diagnose and treat iron deficiency anemia

Screening, Treatment, and Monitoring of Iron Deficiency Anemia in Pregnancy and Postpartum